Diabetes and fracture healing: The skeletal effects of diabetic drugs

Expert Opinion on Drug Safety

Volumn 11, Issue 2, 2012, Pages 215-220

  Simpson, Christopher M ^a   Calori, Giorgio M ^b   Giannoudis, Peter V ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Biguanide; Diabetes; Fracture (+ healing); Insulin; Metformin; Osteogenesis; Rosiglitazone; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; BONE MORPHOGENETIC PROTEIN; GELATINASE B; GLIBENCLAMIDE; GLICLAZIDE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

BONE DENSITY; BONE DEVELOPMENT; BONE MARROW CELL; CELL DIFFERENTIATION; DIABETES CONTROL; DIABETIC PATIENT; DOWN REGULATION; DRUG EFFICACY; DRUG INDICATION; ENZYME ACTIVATION; EXPERIMENTAL STUDY; FRACTURE HEALING; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; MEDICAL LITERATURE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOBLAST; OSTEOPATHIC MEDICINE; PRACTICE GUIDELINE; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SKELETON; SYSTEMATIC REVIEW;

ANIMALS; BONE AND BONES; DIABETES MELLITUS; FRACTURE HEALING; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; OSTEOGENESIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84857389680     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.639359     Document Type: Review

References (32)

1. NHS. Diabetic Prevelence. 2011. Available from: www.diabetes.nhs.uk [Cited 18 April 2011]
2. Chesser TJS, Hammett RB, Norton SA. Orthopaedic trauma in the obese patient. Inj Int J Care Injured 2010;41:247-52
3. NHS H. NHS hospital episode staistics. 2011. Available from: www.hesonline. nhs.uk [Cited 18 April 2011]
4. Zuurmond RG, van Wijhe W, van Raay JJAM, et al. High incidence of complications and poor clinical outcome in the operative treatment of periprosthetic femoral fractures: An analysis of 71 cases. Inj Int J Care Injured 2010;41:629-33
5. Sammour T, Kahokehr A, Caldwell S, Hill AG, et al. Venous glucose and arterial lactate as biochemical predictors of mortality in clinically severely injured trauma patients - A comparison with ISS and TRISS. Inj Int J Care Injured 2009;40:104-8
6. Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991;49:155-60
7. Janghorbani M, Van Dam RM, Willett WC, Hu FB, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495
8. Cozen L. Does diabetes delay fracture healing? Clin Orthop Relat Res 1972;82:134
9. Loder RT. The influence of diabetes mellitus on the healing of closed fractures. Clin Orthop Relat Res 1988;232:210
10. Roszer T. Inflammation as death or life signal in diabetic fracture healing. Inflamm Res 2010;60:3-10
11. Kayal RA, Siqueira M, Alblow J, et al. TNF mediates diabetes enhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis Through FOXO1. J Bone Miner Res 2010;25:1604-15
12. Follak N, Kloting I, Wolf E, Follak H, et al. Improving metabolic control reverses the histomorphometric and biomechanical abnormalities of an experimentally induced bone defect in spontaneously diabetic rats. Calcif Tissue Int 2004;74:551-60 (Pubitemid 38780291)
13. Santana RB, Xu L, Chase L, et al. A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes 2003;52:1502
14. Fowlkes JL, Bunn RC, Liu L, et al. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 2008;149:1697
15. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
16. Ali AA, Weinstein RS, van Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226
17. Shockley KR, Lazarenko OP, Czernik PJ, et al. PPAR 2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009;106:232
18. Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr osteoporos rep 2010;8:178-84
19. Lin TH, Yang RS, Tang CH, et al. PPAR [gamma] inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats. Bone 2007;41:562-74
20. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-{gamma} agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305
21. Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523
22. Beam HA, Russell Parsons J, Lin SS. The effects of blood glucose control upon fracture healing in the BB Wistar rat with diabetes mellitus. J Orthop Res 2002;20:1210-16 (Pubitemid 35363979)
23. Kayal RA, Alblowi J, McKenzie E, et al. Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone 2009;44:357-63
24. Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 2005;65:1013-15 (Pubitemid 41425882)
25. Saito M, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006;17:1514-23 (Pubitemid 44387486)
26. Follak N, Kloting I, Merk H. Influence of diabetic metabolic state on fracture healing in spontaneously diabetic rats. Diabetes Metab Res Rev 2005;21:288-96 (Pubitemid 40716162)
27. Arlt W, Auchus RJ, Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3 -hydroxysteroid dehydrogenase. J Biol Chem 2001;276:16767
28. Berberoglu Z, Yazici AC, Demirag NG. Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2 year follow up study. Clin Endocrinol (Oxf) 2010;73:305-12
29. Cortizo AM, Sedlinsky C, McCarthy AD, et al. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 2006;536:38-46
30. Kanazawa I, Yamaguchi T, Yano S, et al. Metformin enhances the differentiation and mineralisation of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 2008;375:414-19
31. Molinuevo MS, Schurman L, McCarthy AD, et al. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res 2010;25:211-21
32. Gao Y, Li Y, Xue J, et al. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 2010;635:231-6